John Burn-Murdoch

So the ability to quickly spot concerning patterns and

what you're essentially saying is the capital that you already have to literally take those images acts as a constraint on how much AI can then benefit.

So if you've got loads of scanners and loads of scans, AI scales that up massively.

If you're a country like the UK that is quite scan and scanner and broader capital constrained, we will benefit less from what AI is doing.

And also, when we talked about eliminating people, I guess the key thing to note here is that we've not seen a collapse in the number of radiologists, the number of people who read these scans.

It's more that they are now able to do far more of the other valuable parts of their job.

They're processing more scans, as it were.

Well, look, Professor Sir John Bell, thank you so much for answering all of our questions.

And thank you to the listeners for sending those in.

There will be another episode of Radical coming your way very soon.

Thank you to everyone and goodbye.

Hello, I'm John Byrne Murdoch and welcome to Radical.

I'm stepping in for a mole this week while he's away in Scotland filming The Traitors, but I will stay 100% faithful to the ethos of this podcast, where we explore the global trends reshaping our world and the radical ideas that will define our future.

Outside the studio, I'm a columnist and chief data reporter for the Financial Times, where I specialise in using data and evidence to make sense of the big changes happening in the world.

So for this episode, I wanted to explore one of the most profound and often overlooked transformations of our time, the revolution happening in medicine.

In just a generation, diseases that were once considered a death sentence have, in many cases, become treatable, manageable and increasingly survivable.

These advances are having a huge knock-on effect on our lives, and I really want to find out more.

Joining me today is Professor Sir John Bell, Emeritus Regis Professor of Medicine at the University of Oxford.

He's advised the UK government on life sciences, pharmaceutical strategy and COVID testing and played a pivotal role in the development of the AstraZeneca COVID-19 vaccine during the pandemic.

He's currently a partner at Population Health Partners, a firm focused on investing in and advising life science companies, and he previously served on the board of pharmaceutical company Roche.